BACKGROUND: Ingestion by mice of dextran sodium sulfate (DSS) induces colonic vasoconstriction and inflammation, with some of the effects potentially mediated by the vasoconstrictor endothelin-1 (ET-1). METHODS: In this study, mice given 5% 40 kD DSS for 5-6 days had elevated colonic immunostaining for ET-1 and platelet endothelial cell adhesion molecule-1 (PECAM-1). Increased ET-1 can induce microvascular constriction; however, the increase in PECAM-1 is consistent with angiogenesis that could decrease flow resistance. RESULTS: Our measurements of intestinal blood flow, via infused microspheres, suggests that these 2 factors may offset each other, with only a nonsignificant tendency for a DSS-induced decrease in flow. Daily administration of the endothelin converting enzyme inhibitor SM-19712 (15 mg/kg) attenuated DSS-induced increases in colonic immunostaining of ET-1 and PECAM-1. CONCLUSIONS: SM-19712 attenuated histologic signs of tissue injury and inflammation induced by DSS, and decreased the extent of loose stools and fecal blood. However, the inhibitor did not significantly decrease DSS-induced colon shortening or tissue levels of myeloperoxidase (an indicator of neutrophil infiltration).
BACKGROUND: Ingestion by mice of dextran sodium sulfate (DSS) induces colonic vasoconstriction and inflammation, with some of the effects potentially mediated by the vasoconstrictor endothelin-1 (ET-1). METHODS: In this study, mice given 5% 40 kD DSS for 5-6 days had elevated colonic immunostaining for ET-1 and platelet endothelial cell adhesion molecule-1 (PECAM-1). Increased ET-1 can induce microvascular constriction; however, the increase in PECAM-1 is consistent with angiogenesis that could decrease flow resistance. RESULTS: Our measurements of intestinal blood flow, via infused microspheres, suggests that these 2 factors may offset each other, with only a nonsignificant tendency for a DSS-induced decrease in flow. Daily administration of the endothelin converting enzyme inhibitor SM-19712 (15 mg/kg) attenuated DSS-induced increases in colonic immunostaining of ET-1 and PECAM-1. CONCLUSIONS:SM-19712 attenuated histologic signs of tissue injury and inflammation induced by DSS, and decreased the extent of loose stools and fecal blood. However, the inhibitor did not significantly decrease DSS-induced colon shortening or tissue levels of myeloperoxidase (an indicator of neutrophil infiltration).
Authors: Sara A McCartney; Anne B Ballinger; Ivana Vojnovic; Michael J G Farthing; Timothy D Warner Journal: Life Sci Date: 2002-09-06 Impact factor: 5.037
Authors: Thorsten Vowinkel; Mikiji Mori; Christian F Krieglstein; Janice Russell; Fumito Saijo; Sulaiman Bharwani; Richard H Turnage; W Sean Davidson; Patrick Tso; D Neil Granger; Theodore J Kalogeris Journal: J Clin Invest Date: 2004-07 Impact factor: 14.808
Authors: Norman R Harris; Patsy R Carter; Amit Singh Yadav; Megan N Watts; Songlin Zhang; Melissa Kosloski-Davidson; Matthew B Grisham Journal: Inflamm Bowel Dis Date: 2010-09-27 Impact factor: 5.325
Authors: Norman R Harris; Patsy R Carter; Megan N Watts; Songlin Zhang; Melissa Kosloski-Davidson; Matthew B Grisham Journal: Pathophysiology Date: 2011-06-15
Authors: Daniel P Poole; TinaMarie Lieu; Juan Carlos Pelayo; Emily M Eriksson; Nicholas A Veldhuis; Nigel W Bunnett Journal: Am J Physiol Gastrointest Liver Physiol Date: 2015-07-02 Impact factor: 4.052
Authors: Norman R Harris; Patsy R Carter; Seungjun Lee; Megan N Watts; Songlin Zhang; Matthew B Grisham Journal: Inflamm Bowel Dis Date: 2010-05 Impact factor: 5.325
Authors: Dane D Jensen; Michelle L Halls; Jane E Murphy; Meritxell Canals; Fiore Cattaruzza; Daniel P Poole; TinaMarie Lieu; Hon-Wai Koon; Charalabos Pothoulakis; Nigel W Bunnett Journal: J Biol Chem Date: 2014-06-04 Impact factor: 5.157